News
“MERCURIUS™ Total DRUG-seq represents a new frontier in transcriptome-scale compound screening,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “We are empowering scientists to capture ...
The report also profiles emerging innovators bringing AI-powered diagnostics, rapid sepsis panels, and cost-effective molecular tools to market, emphasizing the industry’s ongoing focus on speed, ...
Artificial intelligence is playing an increasingly vital role in modern medicine, particularly in interpreting medical images to help clinicians assess disease severity, guide treatment decisions and ...
Clinilabs, LLC, a leading full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and medical technology development, today announced the appointments of ...
PolarSeal®, the flexible medical device partner, today announces the appointment of Chris Locke as Chief Technology Officer (CTO) – a key strategic move that reinforces its commitment to enabling ...
Small- to medium-sized AAAs (3.5–5.0 cm in women, 3.5–5.5 cm in men) are typically managed with imaging surveillance, as no proven therapeutic interventions currently exist for this patient group.
Strong teeth and healthy gums don’t happen by chance. They come from steady care, done every single day. What you do in small moments adds up to a big difference over time. Most problems don’t start ...
Seed, a microbiome science company, today announced the nationwide retail launch of its clinically validated microbiome innovations at Sprouts Farmers Market. Beginning this week, Seed’s DS-01® Daily ...
NanoHive Medical, LLC, a leading innovative 3D printed spinal implant technology company is pleased to announce that the company has secured the exclusive sublicense of DirectSync Surgical’s ...
The first cohort in the ongoing clinical Phase 2a study EXIST evaluated a lower dose of exidavnemab compared to placebo in patients with Parkinson’s disease. An interim safety review showed that ...
Partnership Combines VERAXA’s Proprietary ADC Technology with OmniAb’s Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors.
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results